Brigitt E. Abbuehl

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.

Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.

Journal: International journal of hematology

Published: November 18, 2017

Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.

Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.

Journal: International journal of hematology

Published: February 16, 2017

Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.

Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: September 11, 2016

Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.

Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: March 25, 2016

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.

Journal: Blood

Published: February 27, 2015

Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.

Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.

Journal: Expert review of clinical pharmacology

Published: February 10, 2015

Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial.

Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: August 13, 2014

BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.

BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.

Journal: Expert review of hematology

Published: May 17, 2014

Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.

Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: February 15, 2014

Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).

Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: January 24, 2014

Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study.

Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: October 07, 2013

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: June 14, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026